Abstracts tagged "Statin-induced myopathies"

Abstract Number: 2364 • 2015 ACR/ARHP Annual Meeting
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive Myopathy Patients without Statin Exposure May Have a Progressive Disease That Worsens Despite Aggressive Immunosuppressive Therapy
Eleni Tiniakou¹, Iago Pinal-Fernandez², Lisa Christopher-Stine³, Jessie Werner⁴, Thomas E. Lloyd⁵, Julie J. Paik⁶, Jemima Albayda⁷, Sonye K. Danoff⁸ and Andrew Mammen⁹, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland, School of Medicine, Baltimore, MD, ⁵Neurology, Johns Hopkins, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁹NIAMS, NIH, Bethesda, MD
Background/Purpose: While the majority of myopathy patients with antibodies recognizing H 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) have had a statin exposure, approximately one third have not. In…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].